Related Experiment Video
Updated: Jun 28, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Does immunosuppressive pharmacotherapy affect isoagglutinin titers?
J-P Chuang1, C-J Hung, S-S Chang
1Department of Surgery, Tainan Hospital, Taiwan.
Transplantation Proceedings
|October 22, 2008
Summary
Maintenance immunosuppressive therapy in kidney transplants does not impact isoagglutinin titers. This finding is crucial for understanding antibody levels in compatible renal transplants and for future research in ABO-incompatible transplantation.
Area of Science:
- Nephrology
- Immunology
- Transplantation Science
Background:
- Successful ABO-incompatible (ABOi) renal transplantation relies on reducing isoagglutinins pre-transplant.
- Low post-transplant isoagglutinin titers correlate with favorable outcomes in ABOi kidney transplants.
- The effect of maintenance immunosuppression on isoagglutinin titers in ABO-compatible transplants remains unclear.
Purpose of the Study:
- To investigate the impact of maintenance immunosuppressive pharmacotherapy on isoagglutinin titer levels in ABO-compatible renal transplants.
- To compare the effects of different immunosuppressive regimens (tacrolimus vs. cyclosporine) on isoagglutinin titers.
Main Methods:
- Analysis of 10 renal transplant recipients (7 living, 3 cadaveric donors).
- Patients received basiliximab induction followed by maintenance immunosuppression with a calcineurin inhibitor, mycophenolate mofetil, and steroids.
- Anti-human globulin isoagglutinin titers were monitored at multiple time points up to 24 weeks post-transplant, without plasmapheresis or IVIG.
Main Results:
- Maintenance immunosuppressive therapy showed minimal influence on isoagglutinin titer levels over a 6-month follow-up period.
- No significant difference in isoagglutinin titers was observed between patients treated with tacrolimus and those treated with cyclosporine.
Conclusions:
- Maintenance immunosuppressive pharmacotherapy does not appear to affect isoagglutinin titer levels in ABO-compatible kidney transplants.
- Further research is warranted to elucidate the mechanisms behind persistent low-level isoagglutinin titers in successful ABOi renal transplant recipients.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:40Cell-mediated Immune Responses
Overview
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...